Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 7/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415378 | 0.91 | HTT (0.45) | KMT2ASMN1; SMN2LMNANAMPTGAA | |
| SCHEMBL4425059 | 0.91 | KMT2A (0.49) | KMT2ASMN1; SMN2LMNAGAAMEN1 | |
| SCHEMBL4412329 | 0.87 | KMT2A (0.42) | KMT2ASMN1; SMN2LMNAMEN1HTT | |
| SCHEMBL4415660 | 0.86 | ALDH1A1 (0.40) | KMT2ASMN1; SMN2LMNAGAAMEN1 | |
| SCHEMBL6509182 | 0.86 | NAMPT (0.46) | KMT2ASMN1; SMN2LMNANAMPTGAA | |
| SCHEMBL4413584 | 0.85 | ALDH1A1 (0.48) | KMT2ASMN1; SMN2LMNAGAAALDH1A1 | |
| SCHEMBL4413687 | 0.84 | TDP1 (0.40) | KMT2ASMN1; SMN2LMNAGAAHTT | |
| SCHEMBL4419968 | 0.84 | L3MBTL1 (0.46) | KMT2ASMN1; SMN2LMNAGAAMEN1 | |
| SCHEMBL4421518 | 0.83 | MAPT (0.42) | KMT2ASMN1; SMN2GAAMEN1MAPT | |
| SCHEMBL4418890 | 0.82 | MEN1 (0.47) | KMT2ASMN1; SMN2LMNAGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | claimed |
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | SLC6A5, SLC1A5, SLC6A3 | KMT2A 1892/4885SMN1; SMN2 4003/4885LMNA 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.